United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

United Therapeutics said the FDA has cleared it to begin the first clinical trial testing whether organs from gene-edited ...

His effort paid off: Tim Andrews, 66, is only the second person known to be living with a pig kidney. Andrews is free from ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., January 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five posters across its ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...